Qualifying Event Proximity, Cardiovascular Risk, and Benefit of Empagliflozin in Patients with Type 2 Diabetes and Stable Atherosclerosis in the EMPA-REG OUTCOME Trial

Background: In type 2 diabetes, the temporal proximity of an atherosclerotic cardiovascular (CV) event can impact prognosis, but whether timing influences sodium glucose co-transporter 2 inhibitor effects is unknown. We explored the association of time from last qualifying CV event before randomization (myocardial infarction [MI], stroke, coronary artery disease or peripheral arterial disease) with CV outcomes and benefit of empagliflozin (EMPA) in EMPA-REG OUTCOME.

Source: Heart, Lung and Circulation - June 23, 2019 Category: Cardiology Authors: J. Udell, B. Zinman, C. Wanner, M. von Eynatten, J. George, I. Zwiener, S. Lund, S. Hantel, D. Fitchett Tags: 416 Source Type: research